From: METTL14 gene polymorphisms decrease Wilms tumor susceptibility in Chinese children
Variables | rs1064034 (cases/controls) | AOR (95% CI) a | Pa | rs298982 (cases/controls) | AOR (95% CI) a | Pa | Combined (cases/controls) | AOR (95% CI) a | Pa | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
TT | TA/AA | GG | GA/AA | 0–4 | 5 | |||||||
Age, month | ||||||||||||
  ≤ 18 | 72/243 | 66/222 | 1.00 (0.68–1.47) | 0.995 | 105/356 | 33/109 | 1.01 (0.65–1.58) | 0.971 | 106/358 | 32/107 | 0.99 (0.63–1.56) | 0.967 |
  > 18 | 144/321 | 121/412 | 0.67 (0.50–0.88) | 0.005 | 216/517 | 49/216 | 0.56 (0.39–0.79) | 0.001 | 216/517 | 49/216 | 0.56 (0.39–0.79) | 0.001 |
Gender | ||||||||||||
 Females | 109/251 | 80/270 | 0.68 (0.49–0.95) | 0.025 | 159/394 | 30/127 | 0.59 (0.38–0.91) | 0.017 | 159/396 | 30/125 | 0.60 (0.39–0.93) | 0.022 |
 Males | 107/313 | 107/364 | 0.87 (0.64–1.18) | 0.371 | 162/479 | 52/198 | 0.78 (0.55–1.11) | 0.172 | 163/479 | 51/198 | 0.76 (0.53–1.09) | 0.134 |
Clinical stages | ||||||||||||
 I | 73/564 | 64/634 | 0.81 (0.57–1.15) | 0.239 | 111/873 | 26/325 | 0.64 (0.41–1.01) | 0.053 | 111/875 | 26/323 | 0.65 (0.42–1.02) | 0.060 |
 II | 61/564 | 52/634 | 0.77 (0.52–1.14) | 0.193 | 88/873 | 25/325 | 0.78 (0.49–1.23) | 0.285 | 88/875 | 25/323 | 0.79 (0.49–1.25) | 0.305 |
 III | 44/564 | 48/634 | 0.94 (0.61–1.44) | 0.781 | 74/873 | 18/325 | 0.64 (0.38–1.10) | 0.105 | 74/875 | 18/323 | 0.65 (0.38–1.10) | 0.111 |
 IV | 28/564 | 17/634 | 0.53 (0.29–0.98) | 0.043 | 37/873 | 8/325 | 0.58 (0.27–1.26) | 0.171 | 38/875 | 7/323 | 0.50 (0.22–1.13) | 0.095 |
 I + II | 134/564 | 116/634 | 0.79 (0.60–1.04) | 0.093 | 199/873 | 51/325 | 0.70 (0.50–0.98) | 0.037 | 199/875 | 51/323 | 0.71 (0.51–0.99) | 0.043 |
 III + IV | 72/564 | 65/634 | 0.79 (0.55–1.12) | 0.183 | 111/873 | 26/325 | 0.62 (0.40–0.98) | 0.039 | 112/875 | 25/323 | 0.60 (0.38–0.94) | 0.026 |